Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

A novel diffusion model generates synthetic atrial fibrosis images to augment data for deep learning, improving prediction of ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Researchers from Queen Mary University of London have developed an AI tool that creates synthetic yet medically accurate models of fibrotic heart tissue (heart scarring), aiding treatment planning for ...

Despite promising technology and FDA clearances, Pulse Biosciences lacks a revenue stream and remains in the testing phase ...

This study presents a novel ultra-high temperature composite with superior ablation resistances up to 3000 °C for 900 s, ...

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance cardiac cryoablation system in treating ...

The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

In the SmartfIRE study, the Thermocool Smarttouch SF catheter showed an 86.9% effectiveness rate among patients treated with high adherence to recommended ablation parameters.

News & events \| $7 million awarded to establish Australia’s first atrial fibrillation ablation clinical quality registry; $7 million awarded to establish Au ...